Literature DB >> 9316004

A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer.

P J Hollen1, R J Gralla, C Cox, S W Eberly, M G Kris.   

Abstract

Despite the availability of several instruments to evaluate quality of life (QL) over time in patients with lung cancer, barriers in measurement remain. This methodological study used LCSS data (Lung Cancer Symptom Scale, a disease- and site-specific QL measure) to examine analysis methods to quantify QL where data needed for serial evaluation may be missing. Data from two large randomized trials, conducted at 30 centers, of a new combination chemotherapy regimen incorporating a new agent for patients (n = 673) with Stage III and IV non-small cell lung cancer were obtained for this study. QL had been prospectively measured at baseline, day 29, and every six weeks thereafter using the LCSS. For the slope analysis (SA) and area under the curve (AUC) analyses, an adjustment score of zero was used to indicate QL on the day of death (mortality adjustment) and each subsequent day until the end of the assessment period. Significant differences in QL, symptom scores and known prognostic factors at baseline were found in the attrition group. SA and AUC analysis allowed inclusion of 581 patients, giving an adequacy rate of 86%. By using a mortality adjustment, an additional 45 patients were included, increasing the inclusion rate to 93%. With the use of the mortality adjustment, QL was shown to decline over the interval, as opposed to rise if the adjustment had not been performed. The conclusions of the study were: (1) analysis for serial data using SA and AUC provides useful, but differing information; (2) when attrition (caused by death) is a factor, a mortality adjustment presented a more accurate assessment of QL as an endpoint; (3) more frequent evaluations of QL will capture rapid changes in patient status and reduce the attrition bias; (4) all patients should be followed until they die; and (5) QL should be given full consideration as a primary endpoint separate from survival.

Entities:  

Mesh:

Year:  1997        PMID: 9316004     DOI: 10.1016/s0169-5002(97)00059-7

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  12 in total

Review 1.  Management of lung cancer.

Authors:  A Melville; A Eastwood
Journal:  Qual Health Care       Date:  1998-09

2.  Loss to follow-up in cohort studies: how much is too much?

Authors:  Vicki Kristman; Michael Manno; Pierre Côté
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

3.  Effect of cigarette smoking on quality of life in small cell lung cancer patients.

Authors:  Jun Chen; Yingwei Qi; Jason A Wampfler; Aminah Jatoi; Yolanda I Garces; Allan J Busta; Sumithra J Mandrekar; Ping Yang
Journal:  Eur J Cancer       Date:  2012-01-12       Impact factor: 9.162

4.  Quality of life and symptom burden among long-term lung cancer survivors.

Authors:  Ping Yang; Andrea L Cheville; Jason A Wampfler; Yolanda I Garces; Aminah Jatoi; Matthew M Clark; Stephen D Cassivi; David E Midthun; Randolph S Marks; Marie-Christine Aubry; Scott H Okuno; Brent A Williams; Francis C Nichols; Victor F Trastek; Hiroshi Sugimura; Linda Sarna; Mark S Allen; Claude Deschamps; Jeff A Sloan
Journal:  J Thorac Oncol       Date:  2012-01       Impact factor: 15.609

5.  Spiritual well-being in lung cancer survivors.

Authors:  Marlene H Frost; Paul J Novotny; Mary E Johnson; Matthew M Clark; Jeff A Sloan; Ping Yang
Journal:  Support Care Cancer       Date:  2013-02-19       Impact factor: 3.603

6.  Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer.

Authors:  Iris Gluck; Felix Y Feng; Teresa Lyden; Marc Haxer; Francis Worden; Douglas B Chepeha; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-09-23       Impact factor: 7.038

7.  Quality of life as a clinical trial endpoint: determining the appropriate interval for repeated assessments in patients with advanced lung cancer.

Authors:  Patricia J Hollen; Richard J Gralla; Cynthia N Rittenberg
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

8.  A randomized trial of the electronic Lung Cancer Symptom Scale for quality-of-life assessment in patients with advanced non-small-cell lung cancer.

Authors:  J C Kuo; D M Graham; A Salvarrey; F Kassam; L W Le; F A Shepherd; R Burkes; P J Hollen; R J Gralla; N B Leighl
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

9.  Cancer symptom response as an oncology clinical trial end point.

Authors:  Laura C Bouchard; Neil Aaronson; Kathleen Gondek; David Cella
Journal:  Expert Rev Qual Life Cancer Care       Date:  2018-06-07

10.  Lung cancer symptoms and pulse oximetry in the prognostic assessment of patients with lung cancer.

Authors:  Sandro J Martins; Nelson Ho; Sueli O Cavamura; Cecilia M Harada; Crystina A Yamamoto; Teresa Y Takagaki
Journal:  BMC Cancer       Date:  2005-07-06       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.